US drugmaker Alexion Pharmaceuticals said it is voluntarily recalling certain lots of Soliris, an intravenous drug for two potentially fatal blood disorders that can damage the kidneys, heart and brain.

The company said the recall was related to its earlier manufacturing process, which had prompted a similar recall in November.

Alexion initiated the recall due to the presence of visible particles found in a single lot of Soliris during a test, it said in a statement.

The company said it did not expect the recall to have any financial impact or interrupt supply of the drug.